Novo Nordisk

News

Novo fails to shrug off investor concern at Q2 update

Novo Nordisk's better-than-expected second-quarter revenues can't outweigh worries about oral Wegovy growth and another CagriSema disappointment.

News

ZEUS delivers a bolt of pain to Novo Nordisk

Novo Nordisk's IL-6 inhibitor ziltivekimab has failed the phase 3 ZEUS trial in heart disease, denting its bid to expand into new therapeutic areas.

News

US judge says Novo Nordisk must face lawsuit over CagriSema

A US judge has ruled that Novo Nordisk must face a lawsuit claiming it defrauded investors with misleading statements about a pivotal CagriSema study.

News

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.

News

Novo's Wegovy pill cleared for weight loss in EU

The EU has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, keeping the company a step ahead of arch rival Eli Lilly.

News

Silhouettes of people behind a dark screen of number sequences

Hacking ring seeks to extort Novo Nordisk after cyberattack

FulcrumSec has reportedly offered data from a Novo Nordisk breach for sale after a $25m ransom was rejected, but has a second breach also occurred?

Novo fails to shrug off investor concern at Q2 update

ZEUS delivers a bolt of pain to Novo Nordisk

US judge says Novo Nordisk must face lawsuit over CagriSema

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Novo's Wegovy pill cleared for weight loss in EU

Hacking ring seeks to extort Novo Nordisk after cyberattack

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Novo Nordisk

Editor's Picks